Table 1. Baseline variables.
| Characteristics | Surgery group (N = 163) | Non-surgery group (N = 151) | P value |
|---|---|---|---|
| Ages | 0.48* | ||
| Median (range) | 51 (26–73) | 55 (28–79) | |
| ECOG scores | 0.89# | ||
| ≤ 2 (N, %) | 157, 96.3% | 145, 96.0% | |
| > 2 (N, %) | 6, 3.7% | 6, 4.0% | |
| Pathological types | 0.45# | ||
| SCC (N, %) | 136, 83.4% | 121, 80.1% | |
| AC (N, %) | 27, 16.6% | 30, 19.9% | |
| FIGO stages | 0.20# | ||
| IB2 (N, %) | 35, 21.6% | 28, 18.5% | |
| IIA1 (N, %) | 27, 16.6% | 39, 25.8% | |
| IIA2 (N, %) | 44, 27.0% | 34, 22.5% | |
| IIB1 (N, %) | 41, 25.2% | 30, 19.9% | |
| IIB2 (N, %) | 16, 9.8% | 20, 13.2% | |
| Radiotherapy schemes | 0.08# | ||
| IMRT (N, %) | 100, 61.3% | 78, 51.7% | |
| 3D-CRT (N, %) | 63, 38.7% | 73, 48.3% | |
| Tumor diameters | 0.14# | ||
| ≤ 4 cm (N, %) | 103, 68.2% | 103, 68.2% | |
| > 4 cm (N, %) | 60, 36.8% | 48, 31.8% | |
| Pelvic lymph node status | 0.16# | ||
| Positive (N, %) | 60, 36.8% | 41, 25.2% | |
| Negative (N, %) | 103, 63.2% | 110, 72.8% | |
| Parametrial invasion | 0.03# | ||
| Yes (N, %) | 56, 34.4% | 70, 46.4% | |
| No (N, %) | 107, 65.6% | 81, 53.6% | |
| Chemotherapy | 0.19# | ||
| 4 cycles (N, %) | 13, 8.0% | 19, 12.6% | |
| 5 cycles (N, %) | 31, 19.0% | 31, 20.5% | |
| 6 cycles (N, %) | 119, 73.0% | 62, 66.9% |
*Mann-Whitney test; #Fisher's exact test; IMRT, intensity-modulated radiotherapy; 3D-CRT, three-dimensional conformal radiotherapy; ECOG, Eastern Cooperative Oncology Group.